Cargando…
LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD)
BACKGROUND: Antibiotics elicit intestinal dysbiosis with short and long-term deleterious effects. A colon-targeted adsorbent, DAV132, prevents dysbiosis in healthy humans and may protect antibiotic-treated patients. METHODS: Hospitalized patients receiving oral/iv fluoroquinolones (FQ) for the treat...
Autores principales: | Ducher, Annie, Vehreschild, Maria J G T, Louie, Thomas J, Cornely, Oliver A, Féger, Céline, Dane, Aaron, Varastet, Marina, de Gunzburg, Jean, Andremont, Antoine, Mentré, France |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776914/ http://dx.doi.org/10.1093/ofid/ofaa515.1902 |
Ejemplares similares
-
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones
por: Vehreschild, Maria J. G. T., et al.
Publicado: (2022) -
LB-3. Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study
por: Muir, Lori A, et al.
Publicado: (2020) -
LB-16. Association Between Universal Face Shield in a Quaternary Care Center and Reduction of SARS-COV2 Infections Among Healthcare Personnel and Hospitalized Patients
por: Hemmige, Vagesh, et al.
Publicado: (2020) -
LB-18. Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation
por: Kared, Hassen, et al.
Publicado: (2020) -
LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection
por: Hammitt, Laura, et al.
Publicado: (2021)